BioWorld

Dec. 1, 2009

Abilify Falters Overseas: Piqued Hunger in Targacept Partnering?

Investors must wait until probably next year to find out exactly what the withdrawal of Abilify's European marketing application means for Targacept Inc.'s chances overseas with lead asset TC-5214 in adjunctive depression therapy. (BioWorld Today) Read More

Terapio: $5M Round 'Transports' ARS, Skin Protein Toward Clinic

AIDS Vaccine Seems Closer, Albeit Still Elusive for Now

NewCo News: Scripps Spinout Xcovery Sees Room for Kinase Improvement

FDA Down-'Draft' Blows Vibativ Aside; Mortality Results Ready

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...